<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183778</url>
  </required_header>
  <id_info>
    <org_study_id>17-00051</org_study_id>
    <nct_id>NCT03183778</nct_id>
  </id_info>
  <brief_title>Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.</brief_title>
  <official_title>Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proof-of-concept controlled-feeding study is to determine whether
      patiromer (Veltassa®, Relypsa, Inc., Redwood City, CA) can be used to maintain normal serum
      potassium concentrations in chronic kidney disease (CKD) patients who are transitioned to a
      plant-rich diet.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in serum potassium concentrations compared to baseline</measure>
    <time_frame>3 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>First Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the first phase (week 1), participants will be transitioned to a plant-rich renal diet, which contains moderate protein (10-15% of kcal), restricts dairy products (1 serving/day), and eliminates high-potassium fruits and vegetables</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Phase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the second phase (weeks 2 and 3), the diet will be altered to provide at-least half of fruits and vegetables from high-potassium sources</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer</intervention_name>
    <description>Patiromer is a drug used for the treatment of hyperkalemia, a condition that may lead to palpitations and arrhythmia.</description>
    <arm_group_label>First Phase</arm_group_label>
    <arm_group_label>Second Phase</arm_group_label>
    <other_name>Veltassa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Research Diet Menu</intervention_name>
    <description>During the study, participants will be asked to consume only the foods provided in the research diet</description>
    <arm_group_label>First Phase</arm_group_label>
    <arm_group_label>Second Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stages 3B-4 CKD (estimated glomerular filtration rate (eGFR) of 15-44 mL/min/1.73m2,
             not treated with dialysis)

          -  No prior treatment with patiromer

          -  Mild hyperkalemia (potassium 5.1 to &lt;6.5 mEq/L) on one of the last two blood tests

          -  No prior episodes of moderate-severe hyperkalemia (potassium ≥6.5 mEq/L) in the past 6
             months

          -  Deemed appropriate for the intervention by the patient's nephrologist, considering the
             patient's prognosis, cognition and pending treatments (e.g., dialysis)

        Exclusion Criteria:

          -  Change in medications that alter potassium homeostasis (e.g., RAAS inhibitors,
             diuretics, β-blockers) in the last month

          -  Diagnosed with bowel diseases or syndromes (e.g., bowel obstruction, major GI surgery,
             short-bowel syndrome, irritable bowel syndrome, inflammatory bowel disease, chronic
             diarrhea)

          -  Dietary restrictions (e.g., allergies) or otherwise unable/unwilling to adhere to
             study diets (excludes dietary restrictions on high-potassium foods)

          -  Pregnant (females) or planning to become pregnant (males and females) during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David St Jules, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Goldfarb</last_name>
    <phone>212 263 0744</phone>
    <email>david.goldfarb@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Goldfarb</last_name>
      <phone>212-263-0744</phone>
      <email>david.goldfarb@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>David St. Jules, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic kidney disease, stages 3B-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

